Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis

Summary

A single-site mutant of prouPA (M5) spared haemostatic fibrin during thrombolysis in dogs. Zymograms of plasma from these dogs showed an unusual inhibitor complex with C1-inhibitor (C1I). Purified C1I added to human plasma enhanced the fibrinspecificity of M5. In the present study, the effect of recombinant human C1I (recC1I) on high-dose M5 and tPA were compared using fluorescein-labeled standardised clots in a plasma milieu. The shortest time to complete clot lysis (maximum rate) was first determined. This was ∼65% per hour for both activators. By contrast, their top fibrin-specific lysis rate (<20% fibrinogen depletion) was less than half maximum (25–30% per hour). Adding recC1I (250–750 μg/ml) did not affect fibrinolysis, but prevented fibrinogenolysis and plasminogen depletion by M5, raising its fibrin-specific lysis rate to the maximum. With tPA, the recC1I modestly attenuated fibrinogenolysis, raising its fibrin-specific rate to about half the maximum. Consistent with this, the t_½ inhibition by C1I was ∼90 min for tPA compared with ∼10 min for tcM5. The t_½ of C1I for plasmin was ∼2 min. Zymograms of plasma after clot lysis indicated that recC1I prevented non-specific tcM5 generation from M5, as evidenced by suppression of tcM5:C1I complexes. In conclusion, recC1I raised the fibrin-specificity of M5 in plasma so that a maximum lysis rate could be achieved without fibrinogenolysis. The inhibition by C1I of nonspecific but not fibrin-dependent plasminogen activation could not be duplicated by other serpins. The findings provide a potential means to optimize both the efficacy and safety of thrombolysis.

Keywords

Fibrinolysis - fibrin-specificity - recC1-inhibitor - mutant ProuPA

• References

• 1 Longstaff C, Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Letters 2005; 579: 3302-3309.
• 2 Braunwald E, Knatterud GL, Passamani ER. et al. Announcement of protocol change in Thrombolysis in Myocardial Infarction Trial (letter). J Am Coll Cardiol 1987; 09: 467.
• 3 Meyer J, Bar F, Barth H. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group. Lancet 1989; 01: 863-868.
• 4 Liu JN, Tang W, Sun ZY. et al. A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. Biochemistry 1996; 35: 14070-14076.
• 5 Sun Z, Liu BF, Chen Y. et al. Analysis of the forces which stabilizes the active conformation of urokinasetype plasminogen activator. Biochemistry 1998; 37: 2935-2940.
• 6 Liu JN, Liu JX, Liu B. et al. A prourokinase mutant which induces highly effective clot lysis without interfering with hemostasis. Circ Res 2002; 90: 757-763.
• 7 Gurewich V, Pannell R, Simmons-Byrd A. et al. Thrombolysis versus bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator. J Thromb Haemost 2006; 04: 1559-1565.
• 8 Pannell R, Kung W, Gurewich V. C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis. J Thromb Haemost 2007; 05: 1047-1054.
• 9 Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic peptide substrates: chemical and clinical usage. Edinburgh: Churchill Livingston; 1979: 128-39.
• 10 Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-234.
• 11 Vassalli JD, Dayer JM, Wohlwend A. et al. Concomitant secretion of prourokinase and of a plasminogen activator specific inhibitor by cultured human monocytes macrophages. J Exp Med 1984; 159: 1653-1658.
• 12 Pannell R, Gurewich V. The activation of plasminogen by single-chain urokinase or by two-chain urokinase - a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69: 22-26.
• 13 Levi M, Roem D, Kamp AM. et al. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993; 69: 141-146.
• 14 Gurewich V, Pannell R, Broeze RJ. et al. Characterization of the intrinsic fibrinolytic properties of prourokinase through a study of plasmin resistant mutant forms produced by site specific mutagenesis of lysine 158. J Clin Invest 1988; 82: 1956-1962.
• 15 Liu J, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-plasminogen activation. A kinetic study using a plasmin-resistant mutant pro-urokinase (Ala-158-rpro-UK). Biochemistry 1992; 31: 6311-6317.
• 16 Liu J, Pannell R, Gurewich V. A transitional state of pro-urokinase which has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 1992; 267: 15289-15292.
• 17 Fath-Odoubadi F, Huehns TY, Al-Muhammad A. et al. Significance of the Thrombolysis in Myocardial infarction scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction. J Am Heart 1997; 134: 62-68.
• 18 Okajima K, Abe H, Binder BR. Endothelial cell injury induced by plasmin in vitro. J Lab Clin Med 1995; 126: 377-384.
• 19 Bennett WR, Yawn DH, Migliore PJ. et al. Activation of the complement system by recombinant tissue plasminogen activator. J Am Coll Cardiol 1987; 10: 627-632.
• 20 Pannell R, Black J, Gurewich V. The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988; 81: 853-859.
• 21 Liu J, Gurewich V. A comparative study of the promotion of tissue plasminogen activator and prourokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 1991; 88: 2012-2017.
• 22 Huisman LG, van Griensven JM, Kluft C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost 1995; 73: 466-471.
• 23 Rao AD, Pratt B, Berke A. et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J. Am Coll Cardio 1988; 11: 1-11.
• 24 Marder VJ. Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. Am J Med 1987; 83: 15-19.
• 25 Harpel PC, Chang TS, Verderber E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma Fibrin I. Evidence for new binding sites in plasmin-degraded Fibrin I. J Biol Chem 1985; 260: 4432-4440.